Individuals with type 1 (T1D) and type 2 diabetes have a higher risk for ischemic stroke, but those with T1D also have a higher risk for hemorrhagic stroke.

Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.

Weight gain combined with late first pregnancy or nulliparity is associated with an increased risk for breast cancer.

Adolescent hyperglycemia and worsening insulin resistance are associated with an increased risk for worsening structural and functional cardiac damage.

Trials have confirmed the efficacy of GLP-1 RAs in achieving clinically sustained weight loss in people with obesity without diabetes.

Simultaneous liver transplant and sleeve gastrectomy yield durable weight loss, resolution of diabetes and hypertension, and a reduction in allograft steatosis development.

Thyroid cancer-associated syndromes, including multiple endocrine neoplasia type 2, were significantly more prevalent than current estimates.

GLP-1 RAs were associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity.

The FDA approved 3 new color additives, a move that will provide manufacturers with a wider range of natural color options to safely be used in food.

General practitioners report more barriers to caring for patients' sexual problems than obstetrician-gynecologists.

Topline data were announced from a phase 3 trial evaluating somapacitan in children born small for gestational age, with Noonan syndrome, or with idiopathic short stature.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.